Etoricoxib Teva

Etoricoxib Teva



Teva Pharma


Concise Prescribing Info
Symptomatic relief of OA, RA, ankylosing spondylitis, & the pain & signs of inflammation associated w/ acute gouty arthritis. Short-term treatment of moderate pain associated w/ dental surgery. Primary dysmenorrhea.
Dosage/Direction for Use
Adult & adolescents ≥16 yr OA 30 mg once daily. May be increased to 60 mg once daily. Max: 60 mg once daily. RA & ankylosing spondylitis 60 mg once daily. May be increased to 90 mg once daily. Once clinically stabilised, may down-titrate dose to 60 mg once daily. Max: 90 mg once daily. Acute gouty arthritis 120 mg once daily. Max: 120 mg daily for 8 days. Acute pain conditions For acute symptomatic period only. Max: 120 mg daily. Post-op acute dental surgery pain 90 mg once daily. Max: 90 mg daily for 3 days. Primary dysmenorrhea 120 mg once daily. Max: 120 mg daily for 8 days in acute symptomatic period. Patients w/ moderate hepatic dysfunction (Child-Pugh score 7-9) Max: 30 mg once daily; mild hepatic dysfunction (Child-Pugh score 5-6) Max: 60 mg once daily.
May be taken with or without food.
Hypersensitivity. Active peptic ulceration or active GI bleeding. Patients who experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 inhibitors. Severe hepatic dysfunction (serum albumin <25 g/L or Child-Pugh score ≥10). Estimated renal creatinine clearance <30 mL/min. Inflammatory bowel disease. CHF (NYHA II-IV). Patients w/ HTN whose BP is persistently elevated >140/90 mmHg & has not been adequately controlled. Established ischaemic heart disease, peripheral arterial disease, &/or cerebrovascular disease. Children & adolescents <16 yr. Pregnancy & lactation.
Special Precautions
Serious hypersensitivity reactions (eg, anaphylaxis & angioedema); discontinue at the 1st appearance of skin rash, mucosal lesions, or any other signs of hypersensitivity. Patients most at risk of developing GI complications w/ NSAIDs; or w/ a prior history of GI disease eg, ulceration & GI bleeding. Increased risk of GI adverse effects in concomitant use w/ any other NSAID or acetylsalicylic acid (even at low dose). Should use shortest duration possible & lowest effective daily dose. Periodically re-evaluate patient's need for symptomatic relief & response to therapy especially those w/ OA. Risk factors for CV events. Not a substitute for acetylsalicylic acid for prophylaxis of CV thrombo-embolic diseases. Monitor renal function in patients w/ preexisting significantly impaired renal function, uncompensated heart failure, or cirrhosis. History of cardiac failure, left ventricular dysfunction, or HTN & in patients w/ preexisting oedema from any other reason. Control HTN before treatment & monitor BP w/in 2 wk after initiation & periodically thereafter. Discontinue if signs of hepatic insufficiency occur, or if persistently abnormal liver function tests (3x upper limit of normal) occur. Rehydrate patients prior to starting therapy. May mask fever & other signs of inflammation. Concomitant use w/ warfarin or other oral anticoagulants. May have moderate influence on the ability to drive & use machines. Contraindicated in pregnancy. Women should not breastfeed during treatment. Not recommended in women attempting to conceive. Elderly.
Adverse Reactions
Abdominal pain. Alveolar osteitis; oedema/fluid retention; dizziness, headache; palpitations, arrhythmia; HTN; bronchospasm; constipation, flatulence, gastritis, heartburn/acid reflux, diarrhea, dyspepsia/epigastric discomfort, nausea, vomiting, oesophagitis, oral ulcer; increased ALT & AST; ecchymosis; asthenia/fatigue, flu-like disease.
Drug Interactions
Increased in prothrombin time INR w/ oral anticoagulants. May reduce effects of diuretics, ACE inhibitors & AIIA. Increased rate of GI ulceration or other complications w/ low-dose acetylsalicylic acid. May increase the nephrotoxic effect of ciclosporin or tacrolimus. Decrease renal excretion & increase plasma levels of lithium. May increase plasma conc & reduce renal clearance of methotrexate. Increase exposure of ethinyl estradiol & oestrogen. Decreased plasma conc w/ rifampicin.
MIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
ATC Classification
M01AH05 - etoricoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs.
Etoricoxib Teva FC tab 120 mg
Etoricoxib Teva FC tab 60 mg
Etoricoxib Teva FC tab 90 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in